TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22027848

Group type: EXPERIMENTAL
Intervention: Power Balance® band
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo band
Number of subjects: 24

Group type: COMPARATOR
Intervention: No band
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Balance test conditions (EOFS, ECFS, EOFoS, ECFoS)
Number of subjects: 24
Study: 19074154

Group type: EXPERIMENTAL
Intervention: Potato-derived HES (6% HES 130/0.42), n=30
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maize-derived HES (6% HES 130/0.4), n=30
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Potato-derived HES
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maize-derived HES
Number of subjects: 60
Study: 17487260

Group type: EXPERIMENTAL
Intervention: Carvedilol in addition to ACE inhibitor
Number of subjects: 141

Group type: COMPARATOR
Intervention: ACE inhibitor without any beta-blocker (control)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 141
Study: 15113451

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (2 x 10(9) CFU/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 11
Study: 12351286

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9654256

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2a (3x10(6) IU, three times weekly for 18 months)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 489
Study: 8270984

Group type: EXPERIMENTAL
Intervention: 20-mg tamoxifen tablet taken once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10-mg tamoxifen tablet taken twice daily
Number of subjects: 30
Study: 2521930

Group type: EXPERIMENTAL
Intervention: Secondary prevention program including physical and behavioral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 31643025

Group type: EXPERIMENTAL
Intervention: Real Talk intervention
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study: 30940108

Group type: EXPERIMENTAL
Intervention: Weight Action Programme (WAP)
Number of subjects: 330
Study: 28030526

Group type: EXPERIMENTAL
Intervention: JE chimeric virus vaccine (JE-CV)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: JE-CV booster vaccination
Number of subjects: 596
Study: 25431482

Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WBMRI)
Number of subjects: 48
Study: 23680389

Group type: EXPERIMENTAL
Intervention: Watching TV
Number of subjects: 120

Group type: COMPARATOR
Intervention: Motion-controlled gaming
Number of subjects: 120

Group type: COMPARATOR
Intervention: Typical video games
Number of subjects: 120
Study: 21868794

Group type: EXPERIMENTAL
Intervention: EZStep with NSAIDs (4-6 weeks)
Number of subjects: 198

Group type: COMPARATOR
Intervention: NSAIDs and physiotherapy (group 2A)
Number of subjects: 198

Group type: COMPARATOR
Intervention: NSAIDs, physiotherapy, and local steroid injection (group 2B)
Number of subjects: 198
Study: 19108925

Group type: EXPERIMENTAL
Intervention: Glucomannan
Number of subjects: 0
Study: 17889121

Group type: EXPERIMENTAL
Intervention: Continuous cyclosporine (CyA) + sirolimus (SRL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sirolimus (SRL) with cyclosporine (CyA) elimination at 3 months post-transplant
Number of subjects: 0
Study: 15370683

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography in patients with achalasia
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography in patients with neoplasms
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (sex‐ and age‐matched)
Number of subjects: 69
Study: 15239872

Group type: EXPERIMENTAL
Intervention: Elective change of intravenous cannulae every 48 hours
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (cannulae only removed if painful, dislodged, or signs of PVT)
Number of subjects: 47
Study: 11122017

Group type: EXPERIMENTAL
Intervention: Liarozole 50 mg
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Liarozole 75 mg
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Liarozole 150 mg
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 9124990

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) administered as dropwise intravenous infusions in a single dose of 4/0.5 g 3 times a day for 5 to 17 days
Number of subjects: 40
Study: 8249561

Group type: EXPERIMENTAL
Intervention: 5 mg tetracaine diluted in 1 ml of 10% glucose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg tetracaine diluted in 2 ml of 10% glucose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg tetracaine diluted in 4 ml of 10% glucose
Number of subjects: 45
Study: 3524172

Group type: EXPERIMENTAL
Intervention: Moricizine therapy (10 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moricizine therapy
Number of subjects: 20
Study: 29802630

Group type: EXPERIMENTAL
Intervention: Implants with keratinized mucosa (Group 1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Implants without keratinized mucosa (Group 2)
Number of subjects: 24
Study: 27203434

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg, monthly intravitreal injections for one year)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg, monthly intravitreal injections for one year)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 327

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 327
Study: 24225307

Group type: EXPERIMENTAL
Intervention: Incremental shuttle walk test (SWT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT)
Number of subjects: 19
Study: 22728576

Group type: EXPERIMENTAL
Intervention: High molecular weight hyaluronic acid (HA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20653757

Group type: EXPERIMENTAL
Intervention: Self-management education
Number of subjects: 824

Group type: COMPARATOR
Intervention: Control group (normative data)
Number of subjects: 824
Study: 18541933

Group type: EXPERIMENTAL
Intervention: DOTS (thrice weekly for 2 months, followed by isoniazid and rifampicin thrice weekly for 4 months)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Daily tuberculosis chemotherapy (daily for 2 months, followed by isoniazid and rifampicin daily for 7 months)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: DOTS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Daily tuberculosis chemotherapy
Number of subjects: 47
Study: 16822137

Group type: EXPERIMENTAL
Intervention: Original performance recordings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tempo-transformed performance recordings
Number of subjects: 0
Study: 12797567

Group type: EXPERIMENTAL
Intervention: 1450 ppm F‐ dentifrice
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: 500 ppm F‐ dentifrice
Number of subjects: 657

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 657

Group type: COMPARATOR
Intervention: Placebo/1450 ppm F‐ dentifrice
Number of subjects: 657

Group type: COMPARATOR
Intervention: Placebo/500 ppm F‐ dentifrice
Number of subjects: 657
Study: 10235547

Group type: EXPERIMENTAL
Intervention: Nilvadipine (3.2 microg/kg) in rabbits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nilvadipine (4 mg/d) orally in NTG patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (vehicle solution) in rabbits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in NTG patients
Number of subjects: 0
Study: 8907805

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg daily for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Captopril 37.5 mg daily for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Indapamide and Captopril
Number of subjects: 31
Study: 1905384

Group type: EXPERIMENTAL
Intervention: Various intervention strategies (re‐educative, persuasive, facilitative, power)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative methods to measure drug usage
Number of subjects: 0
Study: 6342563

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT), consisting of weekly individual psychotherapy for six months
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low-contact treatment, consisting of one brief meeting per month for six months
Number of subjects: 72
Study: 30935454

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27568682

Group type: EXPERIMENTAL
Intervention: Cervical pessary (Arabin® ASQ 65/25/32)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Expectant management (no pessary)
Number of subjects: 380
Study: 26422722

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23725299

Group type: EXPERIMENTAL
Intervention: Evodial (Gambro, Lund, Sweden)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Standard care with saline flushes or blood predilution
Number of subjects: 252
Study: 21840705

Group type: EXPERIMENTAL
Intervention: Immediate epidural analgesia
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Delayed epidural analgesia
Number of subjects: 54
Study: 18627559

Group type: EXPERIMENTAL
Intervention: PNF stretching group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 17596770

Group type: EXPERIMENTAL
Intervention: Aquatic training (60 min in warm water, three times a week for 12 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (habitual leisure-time activities)
Number of subjects: 34
Study: 15346948

Group type: EXPERIMENTAL
Intervention: Immunotherapy with polycomponent vaccine VP-4 (4 or 5 subcutaneous injections at an interval of 5-7 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group receiving basic therapy
Number of subjects: 75
Study: 12190996

Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg three times a day for 2 days (six doses total)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 8
Study: 9807740

Group type: EXPERIMENTAL
Intervention: Allogeneic cell therapy (AlloCT) with human recombinant interleukin 2 (rIL-2) for 3 days to activate donor PBL, followed by infusion of in vitro rIL-2 activated donor lymphocytes combined with 3-day rIL-2 therapy.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Allogeneic cell therapy (AlloCT) with donor marrow cell infusion without further conditioning.
Number of subjects: 13
Study: 7622801

Group type: EXPERIMENTAL
Intervention: Mirtazapine (24‐72 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Trazodone (150‐450 mg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 200
Study: 2515716

Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 320476

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion in addition to antibiotics
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group received appropriate antibiotic regimen alone
Number of subjects: 27
Study: 6753860

Group type: EXPERIMENTAL
Intervention: Ciprofibrate 50 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ciprofibrate 100 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30554519

Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Monthly injectable PrEP
Number of subjects: 554

Group type: COMPARATOR
Intervention: On-demand PrEP
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: PrEP across all hypothetical programs
Number of subjects: 554

Group type: COMPARATOR
Intervention: Cost considerations
Number of subjects: 554

Group type: COMPARATOR
Intervention: Interest in PrEP initiation
Number of subjects: 554
Study: 30411751

Group type: COMPARATOR
Intervention: Black tea
Number of subjects: 17

Group type: COMPARATOR
Intervention: Black tea with milk
Number of subjects: 17
Study: 26671188

Group type: EXPERIMENTAL
Intervention: DZQE
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Combined formula
Number of subjects: 389

Group type: COMPARATOR
Intervention: EZ
Number of subjects: 389
Study: 25152283

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral transversus abdominis plane block with 0.25% ropivacaine 60 ml (group A)
Number of subjects: 40
Study: 22246200

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (50 mg/ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mitomycin C (0.01%)
Number of subjects: 80
Study: 20107141

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (Sprinkles)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Tablets
Number of subjects: 268

Group type: COMPARATOR
Intervention: Nutrivida
Number of subjects: 268
Study: 18206039

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.4 mg qd at 10PM for 3 days, n = 72)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 142
Study: 15234399

Group type: EXPERIMENTAL
Intervention: Pre-treatment with clopidogrel for three days
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard post-procedural treatment (Control)
Number of subjects: 203
Study: 11383794

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 300 mg bolus followed by 1.5 mg.kg(‐1).h(‐1) continuous infusion for 2 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 9493673

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 22
Study: 8364942

Group type: EXPERIMENTAL
Intervention: 10 mg of ketorolac tromethamine
Number of subjects: 207

Group type: COMPARATOR
Intervention: 10 mg of hydrocodone plus 1000 mg of acetaminophen
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 3640135

Group type: EXPERIMENTAL
Intervention: Future Fit cardiovascular health education and fitness program
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 55
Study: 28746076

Group type: EXPERIMENTAL
Intervention: Neublastin 50 μg/kg
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Neublastin 1200 μg/kg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: All neublastin doses
Number of subjects: 176
Study: 26135333

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray during follicular phase (F)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray during luteal phase (L)
Number of subjects: 116
Study: 25713924

Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy (VCE) using the PillCam SB capsule endoscopy system
Number of subjects: 8

Group type: COMPARATOR
Intervention: 13C breath test using BreathID system
Number of subjects: 8
Study: 22811030

Group type: EXPERIMENTAL
Intervention: Sodium nitrate supplementation (10 mg·kg of body mass)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sodium nitrate supplementation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 19649341

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17503683

Group type: EXPERIMENTAL
Intervention: Provider responses to computer alerts regarding guideline recommendations for antihypertensive treatment.
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Inertia of practice among providers.
Number of subjects: 1017
Study: 15709563

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Didactic Lecture
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PBL
Number of subjects: 52
Study: 11349696

Group type: EXPERIMENTAL
Intervention: Adderall (ADL)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 5 mg/dose
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 10 mg/dose
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 15 mg/dose
Number of subjects: 137
Study: 9484545

Group type: EXPERIMENTAL
Intervention: 10 mg of cisapride during fasting
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg of cisapride followed 30 minutes later by ingestion of 300 mL of milk
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo tablet during fasting
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo tablet followed 30 minutes later by ingestion of 300 mL of milk
Number of subjects: 10
Study: 7869731

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg plus Hydrochlorothiazide 25 mg (BN + HCT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus Hydrochlorothiazide 25 mg (CP + HCT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3285831

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 18
Study: 31135090

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (placebo-controlled trial)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Education provided during recruitment
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Child's current poor state of health
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Possibility of improvement in child's health
Number of subjects: 206
Study: 30963591

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus SP1
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (milk without probiotic)
Number of subjects: 36
Study: 28093194

Group type: EXPERIMENTAL
Intervention: High frequency and intensity neuromuscular electrical stimulation (50Hz, 72.90mA, 3 times per week for 1 hour, 12 sessions)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Low frequency and intensity neuromuscular electrical stimulation (5Hz, 13.85mA, 3 times per week for 1 hour, 12 sessions)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High frequency and intensity neuromuscular electrical stimulation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Low frequency and intensity neuromuscular electrical stimulation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 51
Study: 26459650

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 22882673

Group type: EXPERIMENTAL
Intervention: Oral tramadol therapy (50 to 200 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rescue analgesia (topical cream with 3.33% doxepin and 0.05% capsaicin)
Number of subjects: 100
Study: 21126595

Group type: EXPERIMENTAL
Intervention: Transplanted CD34(+) cell dose levels: 2-4 × 10(6) cells/kg, 4-6 × 10(6) cells/kg, >6 × 10(6) cells/kg
Number of subjects: 438
Study: 19692265

Group type: EXPERIMENTAL
Intervention: Pneumonectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 40
Study: 17668526

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and tretinoin 0.025% gel (CLIN/RA gel)
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Individual components (clindamycin phosphate 1.2% or tretinoin 0.025%)
Number of subjects: 4500
Study: 15479494

Group type: EXPERIMENTAL
Intervention: Paclitaxel 100 mg/m2 plus estramustine 280 mg orally 3 times a day
Number of subjects: 163

Group type: COMPARATOR
Intervention: Paclitaxel 100 mg/m2 alone
Number of subjects: 163
Study: 12964350

Group type: EXPERIMENTAL
Intervention: Hydrocellular foam (Allevyn, Smith and Nephew)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcium alginate (Kaltostat, ConvaTec)
Number of subjects: 20
Study: 9825177

Group type: EXPERIMENTAL
Intervention: Nebivolol 5.0 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: d-nebivolol 2.5 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: l-nebivolol 2.5 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Racemic nebivolol (2.5, 5.0, and 10.0 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 14
Study: 8074059

Group type: EXPERIMENTAL
Intervention: Nicotine (15 micrograms/kg) combined with caffeine (5 mg/kg) during activity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nicotine (15 micrograms/kg) during activity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg) during activity
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo during activity
Number of subjects: 20
Study: 2510845

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg elemental zinc daily)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo (capsule identical in appearance and taste with inert substances)
Number of subjects: 494
Study: 31782961

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 123

Group type: COMPARATOR
Intervention: Sleepiness
Number of subjects: 123
Study: 31051248

Group type: COMPARATOR
Intervention: SMS reminder
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Phone reminder
Number of subjects: 709
Study: 29231502

Group type: EXPERIMENTAL
Intervention: Auricular sticking therapy with semen vaccariae, applied every three days for 2 weeks, combined with western medication.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Auricular pseudo-press therapy, applied every three days for 2 weeks, combined with western medication.
Number of subjects: 90
Study: 25788172

Group type: EXPERIMENTAL
Intervention: Portland cement (PC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PC with iodoform (PC + CHI(3))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PC with zirconium oxide (PC + ZrO(2))
Number of subjects: 30
Study: 23524173

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 94